Bionovo has reported positive results from two independent physician surveys, which showed that MF101 could become first-line treatment for menopausal vasomotor symptoms or hot flashes.[...]

This is a big boost for the beleaguered drugmaker. An FDA advisory committee voted unanimously to recommend Bridion for reversing the effects of certain muscle relaxants and helping patients recover more quickly from anesthesia after procedures, although the endorsement came with some caveats - post-marketing studies should address an allergic [...]

Yet another state is suing the drugmaker over allegations of illegally marketing the antipsychotic and concealing side effects that can cause weight gain and diabetes. Between 1996 and 2006, the Connecticut Medical Assistance Programs spent more than $190 million on Zyprexa, and millions more were spent to treat injuries caused [...]

Cutting to the chase, NME approvals are "on pace with a miserable 2007," writes Jim Kumpel of Friedman Billings Ramsey, in an investor note this afternoon. Through the first two months of this year, the FDA has approved 14 New Drug Applications, which is up from 7 last year and [...]

Fremont's Genitope stops work on lymphoma-fighting drug Genitope halted development of its experimental MyVax treatment for non-Hodgkin's lymphoma after U.[...]

With all the handwringing over dry pipelines, clinical trial failures and few regulatory approvals, a pair of Bear Stearns venture capitalists published an interesting analysis in the latest issue of Nature Reviews Drug Discovery and found that pharma and biotech may just improve their odds if they worked together more [...]